Titan Biotech's R&D spend grew 39.5% YoY to ₹18.39 lakhs — generating ₹850 of revenue per ₹1 of R&D. With 100+ products across 7 categories, zero imported technology, and a new health supplement pipeline, this is process innovation that compounds. A deep-dive case study.

Titan Biotech earns ₹53.90 crore from overseas markets across 100+ countries — 34.5% of total revenue. With a 3:1 forex earned-to-used ratio and a net forex surplus of ₹35.75 crore, this small-cap has built genuine international competitive strength. A deep-dive case study.

Titan Biotech's Asset Turnover Ratio tells a powerful story: from 1.18x in FY2015 to a peak of 1.42x during COVID demand to 0.94x during the current capex phase. A deep-dive case study.